Navigation Links
Herborium Group Shareholders Update
Date:10/27/2011

SADDLE BROOK, N.J., Oct. 27, 2011 /PRNewswire/ -- Herborium Group, Inc., (Pinksheets: HBRM) www.herborium.com, a Botanical Therapeutics™ company, announced the following update today.

Dr. Agnes Olszewski, Chairmen and a CEO of Herborium stated: "These are truly exciting times for our Company. Firstly, we have continued our planned advancement to the Bulletin Board exchange by maintaining Herborium' Current Information Status– the highest tier attainable on OTC Pink Sheet Markets.  Additionally, we have many developments coming to fruition as a result of series of new initiatives we have undertaken in the Natural Medicine products space. These developments will play a significant role in Herborium's growth and future."

Dr. Olszewski continued, "As these developments are released to the public it will be important for all current and future shareholders to know what represents a value added and uniqueness of our Company, and where we are progressing along our business plan. Therefore, we felt it necessary to release a short overview of our business opportunity map, before we actually begin discussing the goals we have accomplished and those we are pursuing."

First and foremost Herborium is a natural medicinal products company with a number of established, proprietary, patent and/or trade secret protected natural medicinal products – Botanical Therapeutics®. Our Botanical Therapeutics are uniquely qualified and positioned to address numerous highly important health concerns in both the medical and social spaces. These products are differentiated from most of other natural medicinal products on a market by three distinct characteristics 1) scientific and clinical testing 2) each product targets high demand area of medical needs 3) intellectual property protection. In addition, number of our Botanical Therapeutics is beyond the development stage and is being commercialized or is ready for commercialization. Herborium has also secured a pipeline of product extensions that will assure the Company's positioning  in the marketplace and stream of revenues. The combined market for non-traditional treatments and healthy lifestyles expenditures in the USA alone exceeds $50 Billion with natural medicine being responsible for over 70% of the spending.  The overall potential for botanical drugs may exceed $3 trillion USD worldwide.

Herborium lead Botanical Therapeutic® - AcnEase® , (www.acnease.com is all botanical ingredients based medicine that addresses the need for an effective and safe solution  in the treatment of acne and symptoms of Rosacea.. The National Institute of Arthritis and Musculoskeletal and Skin Diseases Website (Division of National Institutes of Health) reports that in the US alone nearly 85% of people between the ages of 12 and 24 develop acne, and 60 million Americans have existing acne. Rosacea afflicts over 17 million Americans and is a much more prevailing problem in Europe with no known solution in sight.  AcnEase is an all natural systemic product that safely and effectively targets acne and Rosacea in both females and males of all ages.  The results of AcnEase have been impressive with up to 95% of patients seeing improvement after the first course of treatment. Those suffering from symptoms of Rosacea noted up to 90% improvement in skin related symptoms as well as GI and opthomological symptoms.

During the recent months, a significant progress has been made through our marketing efforts, with special focus on Social Marketing strategy, to capitalize on the unique benefits of AcnEase, and on growing consumer needs, exasperated by a recent withdrawal of the Roche Pharmaceutical product - Accutane , the only systemic competition for AcnEas, and by the increasing demand for natural medicines.

Those and other business progress milestones are going to be a subject in our forthcoming communications.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. For more information, please visit www.herborium.com and www.acnease.com.  

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: DrAgnes@Herborium.com


'/>"/>
SOURCE Herborium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):